148 related articles for article (PubMed ID: 34454823)
21. Comparison of Tyrosine Kinase Inhibitor
Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
[TBL] [Abstract][Full Text] [Related]
22. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
[TBL] [Abstract][Full Text] [Related]
23. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
25. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; Santoni M; de Cobelli O; Nolé F
Crit Rev Oncol Hematol; 2016 Mar; 99():324-31. PubMed ID: 26818051
[TBL] [Abstract][Full Text] [Related]
26. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma.
Stenman M; Laurell A; Lindskog M
Med Oncol; 2014 Mar; 31(3):841. PubMed ID: 24477648
[TBL] [Abstract][Full Text] [Related]
28. Role of circulating tumor cells in patients with metastatic clear-cell renal cell carcinoma.
Nayak B; Panaiyadiyan S; Singh P; Karmakar S; Kaushal S; Seth A
Urol Oncol; 2021 Feb; 39(2):135.e9-135.e15. PubMed ID: 33250345
[TBL] [Abstract][Full Text] [Related]
29. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
[TBL] [Abstract][Full Text] [Related]
31. Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.
Li T; Li H; Xie S; Tan Y; Xie ZP; Li WY; Ai F
Pathol Oncol Res; 2020 Apr; 26(2):1319-1324. PubMed ID: 31388933
[TBL] [Abstract][Full Text] [Related]
32. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma.
Ikeda T; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
Target Oncol; 2018 Jun; 13(3):379-387. PubMed ID: 29785576
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
39. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
[TBL] [Abstract][Full Text] [Related]
40. Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors.
Shin SJ; Kim T; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI; Kang M
Clin Genitourin Cancer; 2019 Dec; 17(6):e1137-e1146. PubMed ID: 31473122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
